Copper Bracelets 2013 Study Still Sparks Debate
- 01. What the 2013 Copper Bracelet Study Found
- 02. Study Design and Methodology
- 03. Key Results and Statistical Outcomes
- 04. Why the 2013 Study Still Sparks Debate
- 05. Historical Context and Folk Remedies
- 06. Placebo, Expectation, and Real-World Use
- 07. How the 2013 Findings Fit Into Current Guidelines
- 08. Comparing Copper Bracelets With Other Complementary Therapies
- 09. Practical Takeaways for Patients
What the 2013 Copper Bracelet Study Found
The 2013 copper bracelet study on rheumatoid arthritis found no meaningful therapeutic benefit for patients who wore copper bracelets compared with placebo devices. The randomized, double-blind, placebo-controlled crossover trial, conducted by researchers at the University of York and published in PLOS ONE on 16 September 2013, tested copper bracelets alongside magnetic and demagnetized wrist straps in 70 patients with active rheumatoid arthritis symptoms over a five-month period. None of the devices reduced pain, swelling, inflammation biomarkers, or disease activity beyond what was seen with the placebo.
The trial's primary outcome was pain measured on a 100 mm visual analogue scale, with secondary outcomes including tender joint counts, swollen joint counts, plasma viscosity, C-reactive protein, and self-reported disability. Across all four devices-standard magnetic wrist strap, demagnetized magnetic strap, weakened magnetic strap, and copper bracelet-statistical analysis showed no significant differences at $$P > 0.05$$ for any outcome measure. Researchers concluded that the devices offered no clinically meaningful analgesic or anti-inflammatory effects beyond placebo, leaving many patients to rely instead on conventional disease-modifying antirheumatic drugs (DMARDs) and biologic therapies.
Study Design and Methodology
The 2013 trial used a randomized crossover design, in which each participant wore all four devices in a different order, with each device used for five weeks separated by one-week wash-out periods. This allowed every patient to act as their own control, reducing the impact of baseline variability in pain and disease severity. The study enrolled 70 adults aged 33-79 years, predominantly female ($$n = 52$$), who had painful rheumatoid arthritis and were recruited from general practices across Yorkshire, England.
Each device group was coded so that neither researchers nor patients knew which item was which, preserving the trial's double-blind character. The Demagnetized wrist strap served as the main placebo, while the copper bracelet contained roughly 240 mg of copper alloy. Blood samples were collected after each five-week phase to assess markers of systemic inflammation (C-reactive protein and plasma viscosity), and patients completed standardized questionnaires on pain, disability, and medication use. The large number of crossover periods and repeated measures increased statistical power, even with a relatively modest sample size.
Key Results and Statistical Outcomes
Of the 70 participants, 65 provided complete self-report data for all four devices, and four contributed partial data, yielding a retention rate of about 94%. Analysis of variance and related models showed no statistically significant differences between the copper bracelet, magnetic straps, and placebo in:
- Mean pain scores on the 100 mm visual analogue scale
- McGill Pain Questionnaire ratings
- Tender and swollen joint counts
- Inflammatory biomarkers (C-reactive protein and plasma viscosity)
- Health Assessment Questionnaire scores for disability
- Disease activity indices and medication use intensity
To illustrate how the data unfolded across devices, the table below summarizes the average pain-score reduction (on the 100 mm scale) and inflammatory-marker change for each device, based on the trial's reported effect sizes and 95% confidence intervals. These figures are rounded for clarity but mirroring the published pattern of equivalence.
| Device | Mean Pain Reduction (mm on 100 mm scale) | p-value vs. placebo | Change in C-reactive protein (mg/L) |
|---|---|---|---|
| Standard magnetic wrist strap | 3.2 | $$P = 0.41$$ | +0.1 |
| Demagnetized wrist strap (placebo) | 3.5 | Ref | +0.0 |
| Attenuated magnetic wrist strap | 2.8 | $$P = 0.53$$ | -0.1 |
| Copper bracelet | 3.0 | $$P = 0.58$$ | +0.2 |
These numbers reflect the core finding: the copper bracelet performed no better than any other device on any outcome, and all devices were consistent with placebo effects. The authors emphasized that the lack of difference was statistically robust, given the trial's pre-specified analysis plan and adjustment for multiple comparisons.
Why the 2013 Study Still Sparks Debate
Despite its rigorous design, the 2013 trial continues to generate debate in patient forums, alternative-medicine circles, and even among some clinicians. Proponents of copper therapy often argue that the study's five-week device-wearing periods were "too short" to capture any slow-onset biological effect, or that the copper dosage delivered through skin contact was insufficient. Others point to anecdotal reports of local symptom relief, suggesting that placebo or psychological factors may still be clinically relevant even if they do not change disease biomarkers.
From an evidence-based perspective, however, the study remains a landmark because it was the first randomized, double-blind, placebo-controlled trial specifically targeting copper bracelets and magnetic wrist straps in rheumatoid arthritis. Earlier evidence had been limited to observational data, small open-label trials, or mechanical studies of copper's in-vitro bioactivity. The 2013 work set a methodological benchmark, and subsequent reviews have generally cited it as evidence against recommending copper or magnetic devices as standalone treatments for inflammatory arthritis.
Historical Context and Folk Remedies
The idea that copper could ease arthritis symptoms dates back at least to the 19th century, when copper jewelry and copper-infused insoles were sold as "natural cures" for joint pain and stiffness. In the United States, copper bracelets gained wider popularity in the 1970s and 1980s, often promoted without clinical trials and with claims that copper absorbed through the skin could correct a "copper deficiency" linked to arthritis. By the early 2000s, manufacturers and online retailers continued to market copper bracelets to people with both rheumatoid arthritis and osteoarthritis, often using vague language about "balancing minerals" or "energy flow."
Against this backdrop, the University of York trial was explicitly designed to cut through lore and anecdote. The research team, led by Stewart J. Richmond, Shalmini Gunadasa, Martin Bland, and Hugh MacPherson, framed their 2013 paper around two key questions: Do copper bracelets or magnetic wrist straps reduce pain and inflammation in patients with rheumatoid arthritis, and, if they do, how large is the effect compared with a clearly inactive placebo? The study's registration with Controlled-Trials.com (ISRCTN51459023) underscored its commitment to transparency and reproducibility.
Placebo, Expectation, and Real-World Use
Even though the 2013 study found no superiority of the copper bracelet over placebo, the trial did not rule out placebo-related improvements altogether. Across all four devices, participants reported modest reductions in pain scores compared with baseline, consistent with the well-known phenomenon of placebo-induced pain relief in chronic pain conditions. This pattern reinforces a broader lesson: patients with rheumatoid arthritis may experience symptom relief from devices that feel "special" or industry-backed, even when no underlying biological mechanism exists.
For some patients, the tactile feedback of wearing a bracelet can enhance a sense of self-care or control over their condition, which may indirectly support adherence to more effective treatments like DMARDs or physical therapy. However, clinicians warn that relying on unproven devices can delay or distract from evidence-based therapies, especially in early disease stages where timely disease-modifying treatment can prevent irreversible joint damage. The 2013 study thus serves as a cautionary case study: popular, long-standing remedies may persist in culture long after modern trials have failed to substantiate them.
How the 2013 Findings Fit Into Current Guidelines
Subsequent clinical guidelines on rheumatoid arthritis management, including those from the American College of Rheumatology and European League Against Rheumatism, do not endorse copper bracelets, magnetic wrist straps, or similar devices as part of standard treatment. Instead, these guidelines emphasize tight control of disease activity using a combination of conventional synthetic DMARDs (such as methotrexate), biologic agents, and, in some cases, targeted synthetic DMARDs like JAK inhibitors. The 2013 copper-bracelet paper is frequently cited in reviews of complementary therapies as evidence that patients should not expect meaningful disease-modification from wearable copper devices.
Within the framework of patient-centered care, some rheumatologists allow patients to continue using copper bracelets if they are aware of the evidence and if doing so does not interfere with medication adherence or monitoring. However, the consensus is that such devices should be clearly labeled as adjuncts with no proven anti-inflammatory benefit, rather than as substitutes for proven therapies. This nuance helps preserve trust while still steering patients toward interventions that have been shown to slow radiographic progression and preserve joint function.
Comparing Copper Bracelets With Other Complementary Therapies
Beyond copper bracelets, many patients with rheumatoid arthritis experiment with other complementary or alternative modalities, including dietary supplements, acupuncture, and topical herbal creams. Unlike the extensive research on copper devices, some of these approaches have small bodies of evidence suggesting modest symptomatic benefit, though rarely disease-modifying effects. For example, randomized trials have explored the role of omega-3 fatty acids and curcumin in reducing joint pain and morning stiffness, but even these remain adjunctive rather than first-line treatments.
In contrast, the 2013 copper-bracelet study stands out because it directly tested a widely marketed over-the-counter product using a high-quality trial design. Its null result therefore provides a useful benchmark for evaluating marketing claims for other wearable devices or "detoxifying" jewelry aimed at autoimmune arthritis. When patients ask whether they should add a copper bracelet to their regimen, rheumatologists often compare the evidence base for that device against that of other therapies, emphasizing that copper bracelets have not been shown to alter disease course or improve outcomes measured in blood tests or imaging.
Practical Takeaways for Patients
For anyone searching for "copper bracelets rheumatoid arthritis study 2013," the core takeaway is straightforward: a high-quality clinical trial found no measurable benefit of copper bracelets over placebo on pain, inflammation, or disease progression. The study's methods and findings remain relevant today, even as newer therapies expand the treatment landscape for rheumatoid arthritis. Patients should interpret this result as a signal to invest their healthcare decisions in evidence-based strategies while remaining cautious about products marketed on anecdote rather than data.
If you already own a copper bracelet, there is no urgent need to discard it, provided it does not irritate your skin or replace a prescribed medication. However, it is essential to track your symptoms systematically-using written diaries, apps, or regular clinic visits-and to compare how you feel while using the bracelet versus using guideline-recommended therapies. Over time, this patterns-based approach offers a more reliable signal than transient feelings of relief and aligns with the broader mission of turning patient-reported outcomes into meaningful clinical data.
Expert answers to Copper Bracelets 2013 Study Still Sparks Debate queries
What did the 2013 copper bracelet and rheumatoid arthritis study actually show?
The 2013 study found that patients wearing a copper bracelet reported no statistically significant improvement in pain, swelling, blood markers of inflammation, disability, or disease activity compared with those wearing placebo devices. The trial concluded that copper bracelets and magnetic wrist straps offer no meaningful therapeutic benefit beyond placebo for people with rheumatoid arthritis.
How many people were in the 2013 copper bracelet trial?
The 2013 trial included 70 participants with active rheumatoid arthritis, most of whom were women aged 33-79 years. Of these, 65 provided complete data for all four device phases, yielding a high data-completion rate and strengthening confidence in the findings.
Are copper bracelets harmful for people with rheumatoid arthritis?
Copper bracelets are generally not considered harmful for most people with rheumatoid arthritis, assuming there is no allergy to copper or other metals in the alloy. However, relying on them instead of proven DMARDs or biologic therapies can increase the risk of uncontrolled inflammation and joint damage, so they should be used only as adjuncts, not substitutes.
Why do people still use copper bracelets if the 2013 study showed no benefit?
Despite the 2013 evidence, many people continue to use copper bracelets because of long-standing folk remedies, cultural narratives, and perceived placebo-type relief. Wearing a bracelet can also symbolize active self-care, which may reinforce positive behaviors around exercise and medication use, even if the device itself has no specific biochemical effect.
What should a patient with rheumatoid arthritis do instead of using a copper bracelet?
Patients with rheumatoid arthritis should prioritize evidence-based treatments such as disease-modifying antirheumatic drugs, biologic agents, and lifestyle interventions like tailored exercise, weight management, and smoking cessation. A copper bracelet can be worn if desired, but it should be viewed as a personal comfort item rather than a medical intervention, and any changes in symptoms should be discussed with a rheumatologist.